Group 1 - Guoxin Technology successfully tested its new quantum-resistant password card product CCUPHPQ01, which combines quantum-resistant algorithms with classical national encryption algorithms [3] - The product supports various national encryption algorithms such as SM1, SM2, SM3, SM4, and mainstream quantum-resistant algorithms like Kyber and Dilithium [3] - Guoxin Technology has sent samples to multiple clients, who are developing information security applications based on the new product [3] Group 2 - Huayang New Materials issued a risk warning regarding irrational speculation, clarifying that it does not possess rare earth permanent magnet attributes and its main business is precious metal recycling [4] - The company noted significant stock price fluctuations, with a cumulative increase that deviated from the industry average, indicating potential irrational market behavior [4] - Huayang New Materials faces rising raw material procurement costs due to increasing precious metal prices [4] Group 3 - Guodian Nanrui elected Zheng Zongqiang as the chairman of its ninth board of directors [5] - Daqin Railway appointed Zhang Hongyi as the new general manager following the retirement of the previous general manager [6] Group 4 - Jingyi Equipment expects a year-on-year revenue increase of 36.54% to 42.48%, projecting revenue between 690 million to 720 million yuan for the first half of 2025 [8] Group 5 - Enhua Pharmaceutical's chairman, Sun Pengsheng, increased his stake by purchasing 237,900 shares of the company [10] - Yunlu Co., Ltd. announced that its directors and senior management plan to collectively increase their holdings by 4 million to 12 million yuan [11][12] Group 6 - Guoda Special Materials' chairman proposed a share buyback plan with a total amount between 200 million to 400 million yuan [14] Group 7 - Zhongchao Holdings' subsidiaries won multiple power cable projects with a total bid amount of 1.061 billion yuan, representing 19.29% of the company's audited revenue for 2024 [16]

北京市立方律师事务所 关于江苏恩华药业股份有限公司 董事长增持本公司股票的 法律意见书 北京市立方律师事务所 关于 江苏恩华药业股份有限公司董事长增持本公司股票的 法律意见书 致：江苏恩华药业股份有限公司 北京市立方律师事务所（以下简称"本所"）接受江苏恩华药业股份有限公司 （以下简称"恩华药业"或"公司"）的委托，根据《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司收购管理办法》（以下简称"《收购办法》"）、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作（2025 年修订）》等有关法律、法规和规范性文件的规定，以及本法律意见书出具日以前已 发生或存在的事实发表法律意见，按照律师行业公认的业务标准、道德规范和勤勉 尽责精神，就公司董事长孙彭生先生（以下简称"增持人"）于 2025 年 6 月 16 日 以自有资金通过深圳证券交易所股票交易系统以集中竞价交易方式增持公司 A 股股 票的相关事宜（以下简称"本次增持"）进行专项核查，并出具本法律意见书。 对本法律意见书，本所律师特作如下声明：本所律师依据《证券法》《律师事务 所从事证券法律业务管理办法》和《律师事务所证券法 ...

Group 1 - The company held its seventh board meeting and supervisory board meeting on May 27, 2025, where it approved the proposal to repurchase and cancel part of the restricted stock [1] - The company will repurchase 390,209 shares of restricted stock at a price of 11.15 yuan per share, totaling 4,350,830.35 yuan [1] - After the repurchase and cancellation, the company's registered capital will decrease from 1,016,176,792 yuan to 1,015,786,583 yuan [1] Group 2 - The company notified creditors that they have 45 days from the announcement date to request debt repayment or guarantees [2] - Creditors must submit written requests along with relevant proof documents to the company [2] - The announcement provides contact details for the finance department for creditors to submit their claims [2]

Core Viewpoint - The legal opinion issued by Beijing Lifang Law Firm confirms the legality and validity of the procedures and results of Jiangsu Enhua Pharmaceutical Co., Ltd.'s 2025 first extraordinary general meeting of shareholders [1][6]. Group 1: Meeting Procedures - The extraordinary general meeting was convened by the second meeting of the seventh board of directors on May 27, 2025, and the notice was published on May 28, 2025 [2][3]. - The notice included details about the meeting's time, location, voting rights, and registration methods for shareholders [3][4]. - The meeting was held on June 13, 2025, combining on-site voting and online voting through the Shenzhen Stock Exchange trading system [3][4]. Group 2: Participant Qualifications - A total of 353 participants attended the meeting, representing 487,253,371 shares, which is 5.1838% of the total voting shares [4][5]. - The qualifications of the shareholders and their representatives were verified and deemed valid [5][6]. Group 3: Voting Procedures and Results - The voting was conducted through a combination of on-site and online methods, with the results aligning with the previously announced agenda [5][6]. - The meeting's resolutions required a two-thirds majority approval from the attending shareholders for special resolutions [6].

Meeting Details - The shareholders' meeting of Jiangsu Enhua Pharmaceutical Co., Ltd. was held on June 13, 2025, at 9:00 AM [1] - The meeting combined on-site voting and online voting, with specific voting times outlined for both methods [1] - The meeting was convened by the board of directors and presided over by Chairman Sun Pengsheng [1] Attendance and Voting - A total of 353 participants attended the meeting, representing 539,930,290 shares, which is 53.1335% of the total voting shares [2] - Among the attendees, 6 participated on-site, representing 487,253,371 shares (47.9497% of total voting shares), while 347 participated via online voting [2] - Small and medium investors accounted for 52,943,719 shares, or 5.2101% of the total voting shares [2] Proposal Voting Results - The meeting approved a proposal regarding the repurchase and cancellation of restricted stock, with all involved parties abstaining from voting [3] - The proposal required a two-thirds majority of the valid voting rights present at the meeting to pass, which was achieved [4] Legal Opinion - The meeting was witnessed by lawyers from Beijing Lifang Law Firm, who confirmed that the convening and voting procedures complied with relevant laws and regulations [4]

证券代码：002262 证券简称：恩华药业 公告编号：2025-040 关于回购注销部分限制性股票减资暨通知债权人的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，对公告的虚假记载、误导性 陈述或重大遗漏负连带责任。 江苏恩华药业股份有限公司(以下简称"公司")于2025年5月27日召开了第七届董事会第 二次会议、第七届监事会第二次会议，审议通过了《关于回购注销部分限制性股票的议案》。 根据《上市公司股权激励管理办法》及公司《2024年限制性股票激励计划（草案）》等相关规 定，公司需回购注销激励对象已获授但尚未满足解除限售条件的限制性股票39.0209万股，回 购价格为11.15元/股，公司应支付的回购价款总额为4,350,830.35元。公司完成此次回购注销 后注册资本将由101,617.6792万元减少至101,578.6583万元。具体内容详见公司于2025年5月 28日在《证券时报》及巨潮资讯网（http://www.cninfo.com.cn）上披露的《关于回购注销部 分限制性股票的公告》（公告编号：2025-034），上述事项已于2025年6月13日经公司2025年 第一次临时股东大会审 ...

2025年第一次临时股东大会决议公告 证券代码：002262 证券简称：恩华药业 公告编号：2025-039 江苏恩华药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 2、本次股东大会不涉及变更以往股东大会已通过的决议。 3、为了尊重中小投资者权益（中小投资者是指以下股东以外的其他股东：①上市公司的 董事、监事、高管；②单独或者合计持有上市公司5%以上股份的股东），提高中小投资者对股 东大会重大决议事项的参与度，本次股东大会对中小投资者表决单独计票。 一、会议召开情况 （一）召开时间 现场会议召开时间：2025年6月13日（星期五）上午9：00。 网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具 体时间为2025年6月13日的交易时间，即9:15—9:25，9:30—11:30和13:00—15:00；通过深交 所互联网投票系统投票的具体时间为2025年6月13日9:15至15:00的任意时间。 （二）现场会议召开地点：徐州市经济技术开发区龙湖西路31号恩华科技大厦3楼301会议 室。 1、本次股东大会 ...

北京市立方律师事务所 关于江苏恩华药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 2025 年 6 月 北京市立方律师事务所 关于 江苏恩华药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：江苏恩华药业股份有限公司 根据《中华人民共和国证券法》 、《中华人民共和国公司法》(以下简称"《公司 法》")、《上市公司股东大会规则》(以下简称"《股东大会规则》")、《律师事务 所从事证券法律业务管理办法》(以下简称"《证券法律业务管理办法》") 等 相关法律、法规和规范性文件以及《江苏恩华药业股份有限公司公司章程》(以 下简称"《公司章程》") 的规定，北京市立方律师事务所 (以下简称"本所") 指 派律师出席江苏恩华药业股份有限公司 (以下简称"恩华药业")2025 年第一次 临时股东大会 (以下简称"本次股东大会")， 并出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 告中自行引用本法律意见书中的相关内容， 但恩华药业作上述引用时， 不得因引用 而导致法律上的歧义或曲解。 本所律师根据《中华人民共和国证券法》和《律师事务所证券法律业务管理办 法》相关要求， 按照 ...

Group 1 - The Alzheimer's concept sector declined by 0.90%, ranking among the top declines in the concept sector, with notable declines from companies such as Wanbangde, Tonghua Jinma, and Kanghong Pharmaceutical [1][2] - Among the stocks in the Alzheimer's concept sector, 9 stocks experienced price increases, with Beilu Pharmaceutical, Lisheng Pharmaceutical, and Haizheng Pharmaceutical leading the gains at 4.42%, 3.36%, and 1.77% respectively [1][2] - The Alzheimer's concept sector saw a net outflow of 408 million yuan from major funds, with 22 stocks experiencing net outflows, and 5 stocks seeing outflows exceeding 30 million yuan, led by Tonghua Jinma with a net outflow of 126 million yuan [2][3] Group 2 - The top net inflow stocks in the Alzheimer's concept sector included Beilu Pharmaceutical, Luhua Pharmaceutical, and Meinian Health, with net inflows of 23.6 million yuan, 14.7 million yuan, and 14.2 million yuan respectively [2][3] - The stocks with the highest net outflows in the Alzheimer's concept sector included Tonghua Jinma, Changchun Gaoxin, and Dian Diagnostics, with net outflows of 125.8 million yuan, 53.6 million yuan, and 51.5 million yuan respectively [2][3] - The trading activity in the Alzheimer's concept sector showed significant turnover rates, with stocks like Tonghua Jinma and Wanbangde having turnover rates of 4.80% and 15.18% respectively [2][3]

证券代码：002262 证券简称：恩华药业 公告编号：2025-038 江苏恩华药业股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏恩华药业股份有限公司（ 以下简称：公司）第七届董事会第二次会议于2025年 于2025年6月13日（星期五）召开2025年第一次临时股东大会。公司于2025年5月28日在 《证券时报》和巨潮资讯网站 www.cninfo.com.cn上刊登了《江苏恩华药业股份有限公 司关于召开2025年第一次临时股东大会的通知》（公告编号：2025-035）。 根据《上市公司股东大会规则》的规定，现发布关于召开2025年第一次临时股东大 会的提示性公告，具体内容如下： 一、会议召开的基本情况 司法》《中华人民共和国证券法》《深圳证券交易所股票上市规则》《公司章程》等法 律、法规和相关规定。 现场会议召开时间：2025年6月13日（星期五）上午9：00。 网络投票时间：通过深圳证券交易所（以下简称：深交所）交易系统进行网络投票 的具体时间为2025年6月13日的交易时间，即9:15—9:25，9:30—11:30和13:00— 大会通 ...